AzTrials
AzTrials

Lacrimal Apparatus DiseasesNCT01826734

Analysis of 86 Dacryoliths at the University Hospital Ostrava

An observational study of Lacrimal Apparatus Diseases and Lacrimal Duct Obstruction, run by University Hospital Ostrava at 1 site in Czechia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Background Because dacryoliths occur at low frequency, few studies have focused on their composition. The investigators aimed to present findings from morphological, chemical, and mineralogic analysis of 86 dacryoliths. Read more about this study

Who is it for?
Ages 18 years and older
How many people
86 participants
Where
1 siteCzechia
Study dates
Jan 1994to Jan 2013
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The study population consisted of patients complaining of lacrimation, with subsequent detection and extraction of a dacryolit.

Who may be able to join

  • patients over 18 years of age
  • patients complaining of lacrimation
  • patients following an extraction of a dacryolith

Who cannot join

  • not signing the Informed Consent
  • high risk of surgery (ASA IV)
  • presaccal obstruction treatment
  • revision EDCRs
  • incomplete follow-ups

Trial locations and contacts

1 site in 1 country.

Czechia1 site
  • University Hospital Ostrava

    Ostrava, Moravian-Silesian Region, 70800

Other trials in Czechia

About this study

Official title: Lacrimal Sac Dacryoliths (86 Samples): Chemical and Mineralogic Analyses

Background Because dacryoliths occur at low frequency, few studies have focused on their composition.

The investigators aimed to present findings from morphological, chemical, and mineralogic analysis of 86 dacryoliths.

Methods The team studied 86 dacryoliths obtained during 832 dacryocystorhinostomies (DCR) performed for postsaccal obstruction. The samples were analyzed with atomic infrared spectrometry (80 samples), amino acid analysis (17 samples), scanning electron microscopy, and an electron microprobe with an energy dispersive detector (7 samples).

Read the detailed description

INTRODUCTION It is not unusual to find a stone in the lacrimal sac during dacryocystorhinostomy (DCR). Although patients with dacryolithiasis often have a history of long-term intermittent epiphora, lacrimal sac distention, and/or partial obstruction of the nasolacrimal duct (NLD), dacryoliths are often only detected during DCR. The incidence of dacryoliths in the lacrimal sac of patients that undergo DCR ranges from 6.0-18.0%; however, the incidence of dacryoliths has not been evaluated in the general population. Unfortunately, most published studies on dacryoliths have included quite a small number of samples.

Canalicular concretions have long been associated with canaliculitis caused by actinomycotic infection. However, despite recent, significant progress, an understanding of the pathophysiology of lacrimal sac dacryoliths is still missing. Several predisposing factors have been suggested to contribute to the mechanism that gives rise to dacryolith formation. These factors include age (under 50 years old), sex (increased frequency in females), cigarette smoking, and previous occurrence of chronic dacryocystitis and primary acquired nasolacrimal duct obstruction (PANDO). Recent analyses have shown that dacryolith development may be related to lacrimal sac epithelial and NLD production of a broad spectrum of mucins and expression of two peptide members of the trefoil factor family (TFF), TFF1 and TFF3. Because dacryoliths occur at low frequency, few studies have focused on their composition.

In this study, the authors aimed to present findings from morphological, chemical, and mineralogic analysis of 86 dacryoliths.

MATERIALS AND METHODS A total of 967 primary EDCRs were performed at the Department of Otorhinolaryngology of the University Hospital of Ostrava and at the Department of Otorhinolaryngology of the Frydek-Mistek City Hospital between 1994 and April 2012. Only EDCRs performed for postsaccal stenosis/obstruction (832 procedures) were included in the study. Exclusion criteria were presaccal obstruction treatment, revision EDCRs, and incomplete follow-ups.

The study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, and applicable regulatory requirements. Written consent was obtained from all patients before the initiation of surgery and dacryolith analysis.

Among the group of 832 EDCRs, 86 stones of the lacrimal sac (dacryoliths) were found, including 61/86 (70.9%) in women and 25/86 (29.1%) in men. Clinical information was obtained from patient medical records, including the involved side, the etiology of the nasolacrimal duct (NLD) obstruction, the outcome of EDCR at one year after surgery, the size of the dacryolith, and data from dacryolith analysis. The investigators also performed infrared spectrometry, amino acid analysis, and imaging and morphological analyses with a scanning electronic microscope. The association with cigarette smoking was not examined.

Infrared spectroscopy The authors examined the dacryoliths with Fourier transform infrared spectrometry (FTIR; IMPACT 410, fy Nicolet) and a tableting method with potassium bromide (KBr). Evaluations were performed with OMNIC software, and the obtained spectra were compared with a library of spectra from kidney stones.

Amino acids analysis Proteins in the samples (≤ 20 mg) were hydrolyzed with hydrochloric acid [1,2]. Then, 1 mL of distilled water was added, the solution was filtered, then evaporated at 90 ºC under nitrogen, and the residue was dissolved in 2 mL of 1% aqueous NaOH. An aliquot (~0.5 mg of the initial sample) was transferred to another tube, the volume adjusted to ± 100 µL with 1% NaOH, and a derivatization was performed with ethyl chloroformate (4). Next, gas chromatography in tandem with mass spectrometry with a 7890A and MSD5975C (Agilent) was performed, equipped with a 30-m, VF-17ms capillary column (0.25 mm × 0.15 μm; CP8981 from HPST, Praque). Samples were run at temperatures ramped from 60 to 300 ºC at a rate of 6 ºC /min; split injection (10:1) was employed. Electron impact (EI) mass spectrometry detection at 70 eV was performed at temperatures of 230 ºC for the ion source, 250 ºC for the transfer line, and 150 ºC for the quad. We performed full-scan analyses with a helium-carrier gas flow of 1.2 mL/min.

Imaging and morphological analysis Morphological analyses were performed with a scanning electron microscope (QUANTA FEG 450, FEI Company, WA, USA). An electron microprobe with an energy dispersive detector (EDS) was used for the elemental analysis of the organic matrix of the stone and for the analysis of fine inorganic particulates in the stone.

Statistical analysis For statistical analysis, binomial confidence intervals (CI) for the success rates at the 95% CI were calculated. The two-sample t-test and X2 test were used to evaluate differences in age, sex, and surgical success between groups I and II; p<0.05 was considered statistically significant.

Keywords
dacryolith, dacryocystorhinostomy, composition, chemical analysis, infrared spectrometry, scanning electron microscopy, elemental analysis
Medical subject headings
Lacrimal Apparatus Diseases, Lacrimal Duct Obstruction

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01826734
Study groupRoleWhat they receive
Patients with dacryolitsThe study population consisted of patients following a dacryolit extraction procedure. The extraction procedure was not a part of this study.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The percentage of individual types of amino-acids in the dacryolits

    The obtained dacryolist were assessed physically and chemically. The authors will assess the obtained material for the presence of common amino acids.

    Measured: 18 months

Secondary outcomes (1)
  1. The percentage individual elements in the dacryolits

    The obtained biological material will be assessed as regards to its elemental composition.

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Apr 2013 (estimated)
  2. Study startJan 1994
  3. Primary completionDec 2012
  4. Study completionJan 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
86 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01826734
Sponsor's protocol ID
FNO-ENT-Dacryoliths
Status last verified
Sep 2016
First submitted
22 Mar 2013
Last updated
5 Sep 2016
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Iliadelis ED, Karabatakis VE, Sofoniou MK. Dacryoliths in a series of dacryocystorhinostomies: histologic and chemical analysis. Eur J Ophthalmol. 2006 Sep-Oct;16(5):657-62.

    PubMed 17061214
  • Iliadelis E, Karabatakis V, Sofoniou M. Dacryoliths in chronic dacryocystitis and their composition (spectrophotometric analysis). Eur J Ophthalmol. 1999 Oct-Dec;9(4):266-8. doi: 10.1177/112067219900900402.

    PubMed 10651189
  • Lew H, Lee SY, Yun YS. Measurement of pH, electrolytes and electrophoretic studies of tear proteins in tears of patients with dacryoliths: a novel concept for dacryoliths. Ophthalmologica. 2004 Mar-Apr;218(2):130-5. doi: 10.1159/000076149.

    PubMed 15004503
  • Kominek P, Doskarova S, Svagera Z, Lach K, Cervenka S, Zelenik K, Matousek P. Lacrimal sac dacryoliths (86 samples): chemical and mineralogic analyses. Graefes Arch Clin Exp Ophthalmol. 2014 Mar;252(3):523-9. doi: 10.1007/s00417-013-2501-6. Epub 2013 Oct 30.

    PubMed 24170283

Questions about this trial

What is this clinical trial studying?

An observational study of Lacrimal Apparatus Diseases and Lacrimal Duct Obstruction, run by University Hospital Ostrava at 1 site in Czechia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 5 Sep 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The percentage of individual types of amino-acids in the dacryolits (time frame: 18 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01826734, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in